bluuebunny/crossref_metadata_2025_split huggingface dataset:
93-OR: Low Maternal Insulin Sensitivity Associates with DNA-Related Functions in Human First-Trimester Trophoblast
Authors: BANDRES-MERIZ JULIA , HOCH DENISE , HONEDER SOPHIE , MAJALI-MARTINEZ ALEJANDRO , HERRERA EMILIO , SCHITTMAYER MATTHIAS , BIRNER-GRUENBERGER RUTH , DESOYE GERNOT 
Published: June 2020

In first trimester (FT) of pregnancy the human placenta is rapidly growing making it sensitive to environmental influence. We hypothesized that the altered intrauterine milieu associated with maternal obesity modifies placental proteome and function. We used maternal BMI and leptin as measures of obesity and adiposity, characterized the glucose-insulin axis (glucose, C-peptide, insulin sensitivity (ISHOMA)) and quantified fatty acids (GC) in maternal fasted serum (n=123-323). Among those, only higher C-peptide levels and lower ISHOMA were associated with obesity. Subsequent untargeted proteomics (LC-MS/MS, qTOF Bruker maXis ETD II) in FT placentas (weeks 5-6 p.m.) from lean (n=11) and obese (n=11) women and Principal Component Analysis clustered the samples in two groups. Only ISHOMA differed between both clusters (ISHOMA cluster 1: median 0.95, IQR 0.69-1.17; ISHOMA cluster 2: median 0.57, IQR 0.20 - 1.00, P&lt;0.05). Comparing proteomic profiles between ISHOMA groups (separated by median ISHOMA 0.61) identified 86 proteins enriched in the low ISHOMA cluster (P&lt;0.05, FDR 0.05). Biological processes (KEGG pathway analysis) enriched in this group were related to DNA replication and cell cycle (FDR&lt;0.001). Members of the MCM family, involved in DNA damage response and cell cycle arrest, associated with low ISHOMA. This suggested trophoblast growth related processes depend on ISHOMA. Semi-quantitative in-situ analysis found decreased trophoblast proliferation (Ki67, n=22, Δ -33.4%, p&lt;0.05) and increased apoptosis (TUNEL assay, n=22, 5.6 fold, p&lt;0.05) in the low ISHOMA group. These differences were related to an increased DNA damage (𝛄;;H2AX, n=12, 6.9 fold, p&lt;0.001). We conclude that low ISHOMA associated with maternal obesity in FT of pregnancy induces placental proteome changes related to DNA metabolism. This might alter trophoblast, i.e., placental, growth early in pregnancy, which is known to associate with fetal growth and birth weight.

Disclosure
J. Bandres-Meriz: None. D. Hoch: None. S. Honeder: None. A. Majali-Martinez: None. E. Herrera: None. M. Schittmayer: None. R. Birner-Gruenberger: None. G. Desoye: None.
935-P: Effect of CTRB1/2 RS7202877 (T&gt;G) Polymorphism on Weight Loss Response to Liraglutide Treatment in Greek People with Type 2 Diabetes
Authors: KYRIAZOU ANGELIKI V. , KYRIAKIDOU ARTEMIS , KOUFAKIS THEOCHARIS , VASILOPOULOS YIANNIS , AVRAMIDIS IAKOVOS , BALTAGIANNIS STEFANOS , MANTHOU ELENI , GOULIS DIMITRIOS G. , ZEBEKAKIS PANTELIS , KOTSA KALLIOPI 
Published: June 2020

Previous studies have demonstrated an association between gene polymorphisms and weight loss response to GLP-1 RA therapy. We aimed to evaluate the role of rs7202877 (T&gt;G) polymorphism in CTRB1/2 gene in weight loss response to liraglutide among Greek people with T2D. 116 adults with T2D (51% female, mean BMI 35.4±6.4 kg/m2, mean age 68.3±10.9 years), who had been on treatment with liraglutide for at least 6 months were genotyped for the rs7202877 polymorphism, using real-time PCR. Responders were defined as subjects who lost 3% or more of their baseline weight, whereas non-responders those who lost less than 3% of their initial weight after 3 or 6 months of liraglutide administration. 77 (66%) individuals were classified as responders and 39 (34%) as non-responders. 97 (84%) patients were homozygous for the wild type rs7202877 T allele (TT) and 19 (16%) patients carried one polymorphic G allele (TG). The probability of being weight loss responder was increased by 12%, when carrying the G allele; however, the result did not achieve significance (OR:1.12, 95% 0.4, 3.2, P=0.84). In the response group, weight was reduced by 5.9 kg (95% CI: -6.9, -4.9, P&lt;0.0001) and by 6.4 kg (95% CI: -8, -4.9, P&lt;0.0001) from baseline to 3 and 6 months, respectively. More non-responders were treated with a combination of oral agents and insulin at baseline, compared to responders (OR: 0.25, 95% CI: 0.07, 0.84, P=0.008). Both responders and non-responders exhibited a reduction in HbA1c during the study (-0.9%, P&lt;0.0001 and -0.5%, P=0.008, respectively). The probability of being a weight loss responder was decreased by 26% for every 10 kg increase in baseline weight (adjusted for baseline HbA1c OR: 0.97, 95% CI: 0.95, 0.99, P=0.027). Our findings do not suggest a role of CTRB1/2rs7202877 polymorphism in affecting weight loss response to liraglutide in Greek people with T2D. In contrast, lower baseline body weight might be related to better weight control following treatment with liraglutide.

Disclosure
A.V. Kyriazou: Research Support; Self; Novo Nordisk A/S. A. Kyriakidou: None. T. Koufakis: None. Y. Vasilopoulos: None. I. Avramidis: None. S. Baltagiannis: None. E. Manthou: None. D.G. Goulis: None. P. Zebekakis: None. K. Kotsa: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Sanofi-Aventis, Takeda Pharmaceutical Company Limited. Speaker’s Bureau; Self; Menarini Group. Other Relationship; Self; Novo Nordisk Inc.

Funding
Novo Nordisk (91220)
950-P: Efficacy and Safety of Once-Weekly Dulaglutide Added to Titrated Insulin Glargine, Prandial Insulin, and Oral Agents in Obese Asian T2 Diabetes (T2D) Patients: One Year Real-World Evidence from India
Authors: NIGAM ANANT 
Published: June 2020

Objective: To assess the effect of the addition of a weekly GLP-1 Receptor Agonist, injection Dulaglutide (DU) 1.5mg in obese T2D patients, sub-optimally controlled on titrated basal insulin Glargine (iGL), prandial insulin (iP), metformin and glimepiride (SU).
Methods: We retrospectively observed the impact of addition of DU in 167 patients with HbA1c ≥ 8% for ≥ 16 weeks (wk), all on titrated iGL and also on metformin (n=156; 1.5-2g/d), SU (n=101; 3-4mg/d) and iP (n=75; 10-14 units/d). End points were changes in (i) HbA1c (ii) body weight (iii) doses of iGL and iP (iv) dose of SU at wk 16, 32 and 52. Adverse events and side effects of the combination of DU and iGL were noted.
Results: One hundred sixty-seven patients (89M/78F, age 50±4.5 years, wt.82.8±1.4 kg, BMI 30.1±2.1kg/m2, eGFR 78±4mL/min./1.73m2, 10.3±1.1 years duration of T2D) met the inclusion criteria. After addition of DU, HbA1c was - 1.23% [8.24±0.3 to 7.01±0.2, P&lt;0.0001] at wk 16 in 74 % patients, which decreased to 6.9±0.3% (P=0.1586) in 16% at wk 32, but rose to 7.1±0.1% (P=0.1885) in 10% at wk 42-52. At wk 16, weight was - 2.3 kg (82.8±1.4 to 80.5±1.6, P&lt;0.0001) in 78% patients with a further loss of 1.1±0.7 kg (P&lt;0.0001) in 12% by wk 32, but was stable in others until wk 52. Dose of iGL was - 11.1 units (41.3±10.2 to 30.2±9.1, P=0.0381) in 65% subjects by wk 32, was stable in 28% but rose by 4.1±0.01 units (P=0.0078) in 7% by wk 52. Dose of iP was -5.9±0.03 units (12.5±0.3 to 6.6±0.2, P=0.9700) in 31% patients. Dose of SU had to be reduced by 60% in 75% patients and had to be stopped in others because of minor hypoglycemia. No major hypoglycemia occurred. Side effects with DU were nausea (16.5%), vomiting (15.9%) and diarrhea (6.8%), but none had to stop therapy.
Conclusion: Weekly DU when added to iGL, provides statistically significant glycemic control with weight loss, reduced hypoglycemia risk and insulin doses. This combination therapy is well tolerated.

Disclosure
A. Nigam: Advisory Panel; Self; Intas Pharmaceuticals Ltd., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals, USV Private Limited. Speaker’s Bureau; Self; AstraZeneca, Biocon, Cipla Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Sanofi.
957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program
Authors: BUSE JOHN B. , CROWLEY MATTHEW , ERIKSSON JAN W. , GISLUM METTE , HERTZ CHRISTIN L. , KAISER MARCEL , NIELSEN ANNE MOELLER , HALUZIK MARTIN 
Published: June 2020

The global PIONEER program investigated the efficacy and safety of the first oral glucagon-like peptide-1 receptor agonist, oral semaglutide. Across PIONEER trials, patients with type 2 diabetes (T2D) were randomized to once-daily oral semaglutide (3, 7, 14 mg or flexibly dosed) or comparator. The present exploratory subgroup analysis evaluated the effect of background medications on glycated hemoglobin (HbA1c) and body weight (BW) reductions at the end of trial (week 26, 52 or 78) in five PIONEER trials (3-5, 7-8). Data were analyzed from patients who received oral semaglutide or comparator (sitagliptin, liraglutide or placebo) based on background medication received: metformin, sulfonylurea, sodium-glucose co-transporter 2 inhibitor, insulin or combinations. Baseline characteristics were generally similar across subgroups. Reductions in HbA1c and BW were greater for oral semaglutide vs. comparators (except liraglutide, with similar HbA1c reductions), regardless of background medication (Table). In general, there were no statistically significant interactions between treatment and subgroups. Estimated treatment differences were consistent within each trial and background medication subgroups. These findings support the use of oral semaglutide across a broad population of patients with T2D in combination with other commonly used glucose-lowering agents.

Disclosure
J.B. Buse: Consultant; Self; Cirius Therapeutics, CSL Behring, Neurimmune. Research Support; Self; American Diabetes Association, National Institutes of Health, Novo Nordisk A/S, Patient-Centered Outcomes Research Institute, Sanofi, Tolerion, Inc., vTv Therapeutics. Stock/Shareholder; Self; Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Stability Health. Other Relationship; Self; ADOCIA, AstraZeneca, Dance Biopharm Holdings, Inc., Eli Lilly and Company, MannKind Corporation, NovaTarg Therapeutics, Novo Nordisk A/S, Senseonics, Inc, vTv Therapeutics, Zafgen, Inc. M. Crowley: None. J.W. Eriksson: Advisory Panel; Self; Novo Nordisk A/S. Research Support; Self; AstraZeneca, Novo Nordisk A/S. M. Gislum: Employee; Self; Novo Nordisk A/S. C.L. Hertz: Employee; Self; Novo Nordisk A/S. M. Kaiser: Advisory Panel; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S. Speaker’s Bureau; Self; AstraZeneca, Lilly Diabetes. A. Moeller Nielsen: Employee; Self; Novo Nordisk A/S. M. Haluzik: Advisory Panel; Self; Lilly Diabetes, Sanofi. Consultant; Self; Ethicon US, LLC. Speaker’s Bureau; Self; AstraZeneca, Mundipharma International, Novartis AG, Novo Nordisk A/S.

Funding
Novo Nordisk A/S
96-LB: Diabeloop Closed-Loop System Allows Patients with Type 1 Diabetes (T1D) to Significantly Improve Their Glycemic Control in Real-Life Situation, without Serious Adverse Events: A 6-Month Follow-Up
Authors: AMADOU CORALIE , FRANC SYLVIA , BENHAMOU PIERRE Y. , LABLANCHE SANDRINE , HUNEKER ERIK , CHARPENTIER GUILLAUME , PENFORNIS ALFRED 
Published: June 2020

Objective: Previous trials demonstrated an improvement of glycemic control with the single hormone closed-loop system Diabeloop DBLG1. Therefore, efficacy assessment of this system in real life situation is eagerly awaited. A preliminary analysis of glucose TIR (time-in-range) after a mean of 20 weeks of follow-up was previously communicated. The aim of this report is to present results of TIR and HbA1c after 6-month of follow-up.
Methods: After a run-in period with G6 sensor and usual pump, 25 patients with T1D in Corbeil-Essonne and Grenoble diabetes centers (France) were provided with the commercial setting of DBLG1 System (G6 sensor and Kaleido pump). They were taught to manage it during a one to five days hospitalization. Data on system parameters and glycemic control were collected from a cloud platform. We present here the results of TIR and HbA1c after 6 months of follow-up.
Results: Mean age of patients was 43 years (25-72) with a mean duration of diabetes of 19 years (2-43). All patients were already insulin pump users and 76% of patients were women. The run-in period lasted an average of 7 days (4-15). The mean HbA1c and TIR 70-180 mg/dL before DBLG1 System initiation were respectively 7.9% (5.6 to 8.5 %) [63mmol/mol, 38 to 69 mmol/mol] and 53% (21 to 85%). One patient decided to stop using the system after 2 months due to repeated system disconnections and was therefore excluded from the 6-months analysis. After a mean follow-up of 6 months, mean HbA1c decreased from 7.9% to 7.1% [63 to 54 mmol/mol] (p&lt; 0.001*) and TIR 70-180 mg/dL increased from a mean of 53 to 67% (p&lt;0.0001*). Moreover, TIR &lt; 70 mg/dL decreased from a mean of 2.4 to 1.3% (p = 0.03*). No adverse event was reported. Closed loop was in functional mode for 85% of time. Conclusions: The DBLG1 System confirms its ability to significantly improve glycemic control in real life situation without serious adverse events.

Disclosure
C. Amadou: None. S. Franc: Consultant; Self; Diabeloop SA. P.Y. Benhamou: Consultant; Self; Abbott, Diabeloop SA, Eli Lilly and Company, Insulet Corporation, Novo Nordisk Inc., Sanofi. S. Lablanche: None. E. Huneker: Stock/Shareholder; Self; Diabeloop SA. G. Charpentier: Board Member; Self; Diabeloop SA. A. Penfornis: None.
965-P: Real-World Evidence of the Effect on Glycemic Control with Relatively Simultaneous vs. Sequential Initiation of Basal Insulin and GLP-1 Receptor Agonists
Authors: ROSENSTOCK JULIO , AMPUDIA BLASCO FRANCISCO JAVIER , LUBWAMA ROBERT , PENG XUEJUN V. , BOSS ANDERS H. , SHI LIZHENG , FONSECA VIVIAN 
Published: June 2020

Injectable therapy initiation in T2D is often delayed. This retrospective cohort study evaluated the impact of the timing of initiating both basal insulin and GLP-1 RA in people with uncontrolled T2D (HbA1c ≥9 %) on OADs within 12 months (Optum Humedica database of electronic medical records and claims; 1/1/2011 to 6/30/2017). Study cohorts were defined by the days between initiating the first and second injectable: cohort A ≤30 (simultaneous); B 31-90; C 91-180; D 181-270; E 271-360 (sequential). Endpoints: proportion achieving HbA1c &lt;7 % or &lt;8 % and achieving ≥1 % or ≥2 % reduction in HbA1c at 6 and 12 months after initiating the second injectable. Baseline characteristics (N=6339): mean ± SD age 54 ± 11 years; HbA1c 10.7 ± 1.5 %; weight 108 ± 25 kg; 47% male. Despite slightly higher baseline HbA1c, cohort A had the best glycemic outcomes at 6 and 12 months for all 4 endpoints, followed by cohort B, then no difference between C, D and E (Table). Cohorts C, D and E were significantly less likely to achieve HbA1c &lt;7 % than cohort A (hazard ratios [95% CI]: 0.62 [0.53-0.72]; 0.62 [0.53-0.72]; 0.63 [0.54-0.73]), but cohort B was not (0.87 [0.76-1.01]).
In summary, despite higher baseline HbA1c, addition of a second injectable agent within 90 days of the first led to significantly better glycemic control at 12 months than postponing addition to later in the year in uncontrolled T2D.

Disclosure
J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc., REMD Biotherapeutics. Other Relationship; Self; Applied Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. F. Ampudia Blasco: None. R. Lubwama: Employee; Self; Sanofi US. X.V. Peng: Employee; Self; Sanofi. A.H. Boss: Employee; Self; Sanofi. Stock/Shareholder; Self; Novo Nordisk Inc., Sanofi. L. Shi: None. V. Fonseca: Consultant; Self; Abbott, Asahi Kasei Corporation, AstraZeneca, Bayer Inc., Novo Nordisk Inc., Sanofi. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc. Stock/Shareholder; Self; Amgen, Bravo4health.

Funding
Sanofi
966-P: Effect of Baseline ß-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes
Authors: WANG CHAOFAN , XU WEN , DENG HONGRONG , LIN BEISI , LV JING , ZENG LONGYI , YAO BIN , WENG JIANPING 
Published: June 2020

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic control mainly by enhancing glucose-dependent insulin secretion. Yet patients may have different responses when treated with GLP-1 RAs. This study investigated whether the baseline β-cell function affects the treatment response to exenatide in patients with newly diagnosed T2D.
Methods: In the CONFIDENCE study, 110 patients with newly diagnosed T2D completed 48-week exenatide treatment. Glucose and insulin during fixed breakfast were measured at baseline and 48 weeks. This post-hoc analysis evaluated the effect of baseline β-cell function represented by the disposition index (DI) on treatment response to exenatide.
Results: The 110 patients were 49.6±10 years old, with the baseline HbA1c of 8.0±1.0% and BMI of 25.9±3.0kg/m2. As shown in Table 1, patients with the lowest tertile DI had the highest HbA1c, FPG, PPG and the worst insulin resistance at baseline. After adjusting for the baseline values, the improvements of glycemic control were similar among all tertiles groups, regardless of baseline DI. The effects of lowering weight or BMI were comparable in all groups on the basis of the balanced baseline values.
Conclusion: In newly diagnosed T2D who have relatively good residual β-cell function, DI at baseline may not predict the treatment response to exenatide both on glycemic control and weight reduction.

Disclosure
C. Wang: None. W. Xu: None. H. Deng: None. B. Lin: None. J. Lv: None. L. Zeng: None. B. Yao: None. J. Weng: None.

Funding
National Natural Science Foundation of China (81770821 to W.X.); National Key Research and Development Program of China (2016YFC1304801); Eli Lilly and Company
968-P: Long-Term Quantitative and Qualitative Effect of Dulaglutide in Type 2 Diabetes Patients
Authors: KOUTSOVASILIS ANASTASIOS , SOTIROPOULOS ALEXIOS , PAPPA MARIA , PEPPAS THEODOROS 
Published: June 2020

Background: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist GLP-1.
Aim: The aim of the study was to investigate dulaglutide’s quantitative and qualitative long-term effects in type 2 diabetes patients with unsatisfactory glycemic control.
Material and Methods: 310 patients under treatment with dulaglutide were included in the study. Parameters of glycemic control (HbA1c, Fasting Blood Glucose -FBG) and cardiovascular risk factors (weight, body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, LDL, HDL, and triglycerides) were recorded, while treatment satisfaction was evaluated with the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Follow up period was 52±2 weeks with assessment of study’s parameters at 12 ±2 weeks and 24±2 weeks. All the data were collected for 254 patients.
Results: Patients’ age was 60.23±10.21 years. A reduction of HbA1c was during the follow-up period. HbA1c was reduced from the baseline at the 3, 6 and 12 month monitoring times (8.0±1.31 vs. 7.0.9±0.9 vs. 6.97±1.1, vs. 6.77±0.9) p&lt;0.0001). Bodyweight was also reduced during the same monitoring times (96.30 ±20.24 vs. 92.41±18.52 vs. 90.04±18.77, vs. 89.49±18.27, p=0.001). Statistically significant change on waist circumference (p=0.010). A statistically significant reduction was noticed on LDL (p=0.022), triglycerides (p=0.016) while the improvement on HDL was not significant (p=0.108). There was a reduction of the systolic blood pressure (p=0.088) and of the diastolic blood pressure (p=0.114). Treatment satisfaction was improved as evaluated via DTSQ on both Group A (p = 0.026)
Conclusion: The long-term use of dulaglutide leads to a significant reduction of HbA1c and to significant improvement of cardiovascular risk factors from the first three months of dulaglutide’s use. All these parameters are showing a steady improvement during the first twelve months of dulaglutide’s use in type 2 diabetes with an unsatisfactory glycemic control.

Disclosure
A. Koutsovasilis: None. A. Sotiropoulos: None. M. Pappa: None. T. Peppas: None.
PERTUMBUHAN DAN HASIL TIGA VARIETAS KEDELAI DI GAWANGAN DENGAN PEMOTONGAN UJUNG PELEPAH KELAPA SAWIT
Authors: Effendy Iqbal , Novianto Novianto , Utami Dia 
Published: June 2020

Oil palm plantations in Indonesia are the largest one in the world, reaching 12.3 million hectares, around 46% are smallholders with very low productivity couse income of oil palm farmers is very low. One effort to take over the problems is to develop an intercroping pattern of soybean- oilpalm by trimming the tips of the midribs of oil palm plants on thewider side of interspace of palm stand rows, to increase light interception accepted by soy bean plant surfaces. This study used a randomized block design (RBD) arranged in factorial 4x3 with three replications. The first treatment is cutting the edge of the oil palm midrib, namely P1 = 50 cm, P2 = 100 cm, P3 = 150 cm. The second treatment was low light intensity tolerant soybean varieties, namely: V1 = Dena 1, V2 = Anjasmoro and V3 = Detam 1. Other actions were carried out according to generally accepted standards. To see the effect of treatment carried out the F test at the level of 5%, and continued with the HSD test at the level of 5% to see the difference among treatments. The results showed that a hope of developing soybean plants as intercrops, although statistically did not show a significant difference. FFB results were not significantly affected by the act of trimming the midrib as 150 cm.
Vuosipäiväjournalismi historian tulkitsijana ja nykyisyyden muokkaajana: Kehysanalyyttinen tutkimus EU:n historiaa käsittelevistä vuosipäiväjutuista kolmessa suomalaisessa päivälehdessä
Authors: Ikäheimo Hannu-Pekka , Seuri Olli 
Published: June 2020

Tässä artikkelissa analysoidaan, miten kolme suomalaista päivälehteä esittävät EU:n historiaa ja Suomen EU-historiaa. Aihetta lähestytään tärkeitä merkkipäiviä – Rooman sopimuksen solmiminen, Suomen EU-jäsenyys, Suomen Emu-jäsenyys – käsittelevän vuosipäiväjournalismin kautta. Aineisto kattaa vuodet 1995–2019. EU:ta koskevien vuosipäiväjuttujen kehysanalyysistä ja sisällönanalyysistä käy ilmi, että suomalaisilla sanomalehdillä, toimittajilla ja poliittisella eliitillä on vahvasti jaettu käsitys EU:n historiallisesta ja poliittisesta merkityksestä. EU nähdään menestystarinana, eikä merkkejä konsensuksen murtumisesta näy edes 2000-luvulla kumuloituvien kriisien keskellä. Määrällisessä kehysanalyysissä arvopainotus näkyy normaalisti journalismissa vähän esiintyvän moraalikehyksen yleisyytenä. Se myös vankistaa kuvaa vuosipäiväjournalismista erityisenä kerronnan lajinaan. Tutkittujen lehtien perusteella Euroopan integraatioon liittyvillä vuosipäivillä on vakiintunut asema suomalaisessa journalismissa. Aineistosta on kuitenkin havaittavissa kaksi erilaista juonnetta: Euroopan unionin historia esitetään harmonisena, kun taas vasta 1990-luvulta alkavaan Suomen EU-historiaan liittyy myös ristiriitoja ja poliittisia jännitteitä. Mitä kauempana tapahtumat ovat (maantieteellisesti, ajallisesti ja kulttuurisesti), sitä ristiriidattomampana ne sanomalehdessä esitetään.